Today: 16 July 2026
Broadcom stock pops as AVGO flags $100 billion AI chip path and ramps buybacks

Broadcom stock pops as AVGO flags $100 billion AI chip path and ramps buybacks

NEW YORK, March 5, 2026, 12:43 p.m. ET — Regular session

  • Broadcom gained roughly 4% midday, with investors reacting to fresh longer-term AI chip revenue targets from the company.
  • Management raised its short-term outlook and unveiled a new $10 billion buyback plan.
  • U.S. equities slipped, with heightened energy-price risk from the Middle East conflict leaving investors on edge before Friday’s payrolls report.

Broadcom shares climbed 4.3% to $331.12 as of 12:35 p.m. ET, having bounced between $323.54 and $342.14 earlier in the day.

Broadcom jumped after it positioned itself as set to gain more from data-center expansion, despite ongoing skepticism over whether Big Tech’s AI bets will deliver. Summit Insights analysts described Broadcom’s prospects as “broadening rather than peaking,” while Melius Research flagged around 10 gigawatts of AI demand in 2027, citing customers like Anthropic and Meta. Reuters

Broadcom came out late Wednesday with a second-quarter revenue outlook of around $22.0 billion, topping what analysts were looking for, and sees AI chip sales hitting $10.7 billion. CEO Hock Tan told analysts there’s “line of sight” to AI chip revenue surpassing $100 billion in 2027, after AI revenue in the latest quarter more than doubled to $8.4 billion. D.A. Davidson’s Gil Luria called the company’s unusually long-range guidance on demand both rare and a positive sign. Reuters

Custom processors are central to the argument here: specialized chips built for a specific task, meant to supplement—or in some cases, take over from—the expensive general-purpose AI chips that have become standard in data centers. Supply chain issues come into play as well. High-bandwidth memory, which sits next to AI processors as stacked memory, has been a persistent choke point for the industry.

Broadcom put emphasis on rewarding shareholders, greenlighting a fresh $10 billion buyback plan set to run through Dec. 31, 2026. The quarterly dividend stays unchanged at $0.65 per share. Free cash flow for the quarter came in at $8.01 billion, with the company saying it handed back $10.9 billion to investors via dividends and buybacks.

Elsewhere, the tape wasn’t as cooperative. Major indexes on Wall Street slipped while the Middle East conflict rolled into its sixth day, fueling concerns about pricier energy and shipping—potential triggers for stubborn inflation and new headaches for the Fed. “If energy stays expensive, inflation could start climbing again and that would force the Fed to rethink its plans,” said Adam Sarhan, chief executive of 50 Park Investments. Reuters

This trade isn’t bulletproof. Should AI capital spending tap the brakes, or if component shortages start to pinch shipments, Broadcom’s longer-term target gets shakier—and that hefty stock premium could unravel quickly.

Investors have their eyes on two things right now: Broadcom’s post-earnings rally and whether it lasts through the session, plus Friday’s U.S. non-farm payrolls—a data point that could shake up rate bets as energy prices remain unsettled.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • AtaiBeckley (NASDAQ: ATAI) Soars 31% After Lilly $3.8B Buyout Bid
    July 16, 2026, 10:45 AM EDT. Shares of AtaiBeckley shot up 31% to $7.04 after Eli Lilly launched a $6.75-a-share cash bid, putting the deal value at up to $3.8 billion. Traders pushed the price $0.29 above the offer, betting on the $2.50 per share CVR tied to drug pipeline goals. About 80% of the CVR hinges on VLS-01, now in Phase 2b as a psychedelic treatment, with another 20% tied to BPL-003, which has FDA breakthrough status. The sale is expected to close in Q3, if it clears shareholder and regulatory hurdles. The market is treating most of the current price as cash and leaving some room for the CVR milestones, which still need regulatory and DEA signoffs.
Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom
Previous Story

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

AppLovin Lands Stagwell Tie-Up as Mobile Gaming Ads Push Into Brand Budgets
Next Story

AppLovin Lands Stagwell Tie-Up as Mobile Gaming Ads Push Into Brand Budgets

Go toTop